Prevalence of Buprenorphine Providers Requiring Cash Payment From Insured Women Seeking Opioid Use Disorder Treatment

• Published in: Medical care Vol. 61; no. 6; p. 377
• Main Authors: Richards, Michael R, Leech, Ashley A, Stein, Bradley D, Buntin, Melinda B, Patrick, Stephen W
• Format: Journal Article
• Language: English
• Published: United States 01.06.2023
• Subjects: Analgesics, Opioid - therapeutic use; Buprenorphine - therapeutic use; Female; Humans; Medicaid; Opiate Substitution Treatment - methods; Opioid-Related Disorders - drug therapy; Opioid-Related Disorders - epidemiology; Prevalence; United States; United States
• ISSN: 1537-1948
• DOI: 10.1097/MLR.0000000000001851

Medications for opioid use disorder (OUD) are known to be effective, especially in reducing the risk of overdose death. Yet, many individuals suffering from OUD are not receiving treatment. One potential barrier can be the patient's ability to access providers through their insurance plans. We used an audit (simulated patient) study methodology to examine appointment-granting behavior by buprenorphine prescribers in 10 different US states. Trained callers posed as women with OUD and were randomly assigned Medicaid or private insurance status. Callers request an OUD treatment appointment and then asked whether they would be able to use their insurance to cover the cost of care, or alternatively, whether they would be required to pay fully out-of-pocket. We found that Medicaid and privately insured women were often asked to pay cash for OUD treatment--40% of the time over the full study sample. Such buprenorphine provider requests happened more than 60% of the time in some states. Areas with more providers or with more generous provider payments were not obviously more willing to accept the patient's insurance benefits for OUD treatment. Rural providers were less likely to require payment in cash in order for the woman to receive care. State-to-state variation was the most striking pattern in our field experiment data. The wide variation suggests that women of reproductive age with OUD in certain states face even greater challenges to treatment access than perhaps previously thought; however, it also reveals that some states have found ways to curtail this problem. Our findings encourage greater attention to this public health challenge and possibly opportunities for shared learning across states.